Nicergoline
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Nicergoline: From Cerebrovascular Disorders to Hypertrichosis
One-Sentence Summary
Nicergoline is an ergot alkaloid derivative historically used for cerebrovascular insufficiency and cognitive impairment across multiple markets. The TxGNN model predicts it may have activity in Hypertrichosis, with 0 clinical trials and 0 publications currently supporting this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cerebrovascular disorders / cognitive impairment (no India registration on record) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on publicly known pharmacology, Nicergoline is an ergot alkaloid derivative with α-adrenergic receptor blocking activity (both α1 and α2 subtypes) and vasodilatory properties. It has been approved and used in several countries for cerebrovascular insufficiency, peripheral vascular disease, and vascular dementia.
The theoretical link to hypertrichosis — defined as abnormal excessive hair growth — rests on the fact that α-adrenergic receptors are expressed in hair follicles, and adrenergic signaling is known to modulate the hair growth cycle (anagen/telogen transitions). Blocking α receptors could theoretically influence follicular activity and hair shaft production. However, this mechanistic pathway is highly speculative and extrapolated indirectly from receptor biology rather than from any Nicergoline-specific experimental data.
No supporting preclinical or clinical literature connecting Nicergoline to hypertrichosis was identified during evidence collection. The prediction is most likely driven by indirect knowledge graph topology in TxGNN (network proximity between α-receptor pharmacology nodes and hair follicle biology nodes) rather than a validated biological hypothesis. This signal should be treated as hypothesis-generating only and does not currently justify clinical translation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
No product registrations found. Nicergoline is not currently marketed in India.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is zero clinical or preclinical literature specifically linking Nicergoline to hypertrichosis, and no mechanistic precedent beyond a speculative α-receptor/hair-follicle connection. An L5 evidence rating with no supporting data does not justify further development investment for this indication at this time.
To proceed, the following is needed:
- Obtain a CDSCO-recognised package insert or equivalent regulatory document to confirm the original approved indication, key warnings, and contraindications
- Retrieve full DrugBank MOA profile to formally characterise the α-adrenergic blocking and vasodilatory mechanisms
- Conduct a targeted literature search on α-blocker class effects and hair follicle biology to assess whether a biologically plausible hypothesis can be built
- Reassess indication priority: Among the top 8 TxGNN predictions in this pack, two candidates carry substantially stronger mechanistic rationale and should be considered as the primary repurposing focus:
- Benign Prostatic Hyperplasia (Rank 5, 99.39%) — Nicergoline is an α1-blocker, the same pharmacological class as first-line BPH agents (tamsulosin, alfuzosin, doxazosin); a class-effect hypothesis is scientifically defensible and warrants a dedicated literature and clinical trial search
- Migraine Disorder (Rank 8, 99.12%) — Supported by experimental evidence in migraine animal models (PMID 2622296), in vitro serotonin transport studies (PMID 2625145, 8374139), and a direct clinical use report from 1984 (PMID 6385484); this represents the historically best-documented repurposing signal for Nicergoline in this dataset
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.